

## Special Issue

# Therapeutic Strategies and Targets to Improve the Efficacy of PD-1/PD-L1 Blockade

### Message from the Guest Editor

Programmed cell death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) are the hottest drug targets in cancer immunotherapy. Increasing numbers of researches are focusing on the combination therapies to cope with the low average response rate of PD-1/PD-L1 antibody blockade therapy in cancer and other indications. The combinational strategies include the use of Toll-like receptor (TLRs) and STING agonist vaccines, cytokines, nanomedicines, radiotherapy or chemotherapy to activate the innate immunity or induce tumor cell death. In addition, the combination with various targets and their drugs to achieve the purpose of activating innate and adaptive immunity are ongoing. This Special Issue aims to improve the efficacy of PD-1/PD-L1 blockade in cancer and expand the knowledge on a wide range of topics in this field.

---

### Guest Editor

Prof. Dr. Yanfeng Gao

School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Guangzhou, China

---

### Deadline for manuscript submissions

closed (25 July 2024)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/101362](https://mdpi.com/si/101362)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)